risperidone has been researched along with Multiple Sclerosis in 7 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report a case of risperidone-induced Pisa syndrome in a patient with multiple sclerosis (MS) that resolved with lurasidone, recurred with chlorpromazine, and was complicated by possible drug-drug interactions." | 7.79 | Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine. ( Diefenderfer, LA; Iuppa, CA, 2013) |
| " Given the potential of these drugs to modulate the immune system both peripherally and within the central nervous system, we investigated the ability of the atypical anti-psychotic agent, risperidone, to modify disease in the animal model of multiple sclerosis (MS)4, experimental autoimune encephalomyelitis (EAE)." | 3.80 | Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis. ( Connor, B; Fong, D; Green, L; Kharkrang, M; La Flamme, AC; O'Sullivan, D; Stone, S; Zareie, P, 2014) |
| "To report a case of risperidone-induced Pisa syndrome in a patient with multiple sclerosis (MS) that resolved with lurasidone, recurred with chlorpromazine, and was complicated by possible drug-drug interactions." | 3.79 | Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine. ( Diefenderfer, LA; Iuppa, CA, 2013) |
| "Cuprizone and drugs were administered to C57BL6/J mice for five weeks and locomotor activity, motor performance and cold sensitivity were assessed." | 1.62 | Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress. ( Andrei, C; Chirita, C; Ciotu, CI; Fischer, MJM; Mihai, DP; Negres, S; Nitulescu, GM; Olaru, OT; Seremet, OC; Ungurianu, A; Zanfirescu, A; Zbarcea, CE, 2021) |
| "Risperidone was given for ongoing delusions." | 1.56 | Manic episode in patient with bipolar disorder and recent multiple sclerosis diagnosis: A case report. ( Wichser, L; Yang, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, S | 1 |
| Wichser, L | 1 |
| Mihai, DP | 1 |
| Ungurianu, A | 1 |
| Ciotu, CI | 1 |
| Fischer, MJM | 1 |
| Olaru, OT | 1 |
| Nitulescu, GM | 1 |
| Andrei, C | 1 |
| Zbarcea, CE | 1 |
| Zanfirescu, A | 1 |
| Seremet, OC | 1 |
| Chirita, C | 1 |
| Negres, S | 1 |
| Iuppa, CA | 1 |
| Diefenderfer, LA | 1 |
| O'Sullivan, D | 1 |
| Green, L | 1 |
| Stone, S | 1 |
| Zareie, P | 1 |
| Kharkrang, M | 1 |
| Fong, D | 1 |
| Connor, B | 1 |
| La Flamme, AC | 1 |
| Espinosa, PS | 1 |
| Berger, JR | 1 |
| Reiss, JP | 1 |
| Sam, D | 1 |
| Sareen, J | 1 |
| Hussain, A | 1 |
| Belderbos, S | 1 |
7 other studies available for risperidone and Multiple Sclerosis
| Article | Year |
|---|---|
Manic episode in patient with bipolar disorder and recent multiple sclerosis diagnosis: A case report.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lithium Compounds; Middle | 2020 |
Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress.
Topics: Animals; Corpus Callosum; Cuprizone; Disease Models, Animal; Drug Evaluation, Preclinical; Febuxosta | 2021 |
Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine.
Topics: Adult; Antipsychotic Agents; Child Development Disorders, Pervasive; Chlorpromazine; Gait Ataxia; Hu | 2013 |
Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.
Topics: Animals; Antigens; Antipsychotic Agents; Cell Survival; Cytokines; Disease Models, Animal; Dose-Resp | 2014 |
Delayed fingolimod-associated asystole.
Topics: Administration, Oral; Antipsychotic Agents; Bradycardia; Electrocardiography; Fingolimod Hydrochlori | 2011 |
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delusions; Excitatory Amino Acid Antagonists; Female; | 2006 |
Risperidone depot in the treatment of psychosis associated with multiple sclerosis -- a case report.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Middle Aged; Multiple Sclerosis; | 2008 |